• Channels
    • All News
    • In Focus
    • Special
    • AI
    • Bioregnum
    • Biotech Voices
    • Cell/Gene Tx
    • China
    • Coronavirus
    • Deals
    • Diagnostics
    • Discovery
    • FDA+
    • Financing
    • Health Tech
    • Law
    • Letters to the Editor
    • Manufacturing
    • Marketing
    • Nikkei Biotechnology
    • Opinion
    • Outsourcing
    • Peer Review
    • People
    • Pharma
    • R&D
    • Startups
    • Weekly
  • Webinars
  • Biopharma Jobs
  • More
    • Work at Endpoints
    • Letter to Editors
    • Editorial Standards
    • IPO Tracker
    • Webinars
    • Events
    • Sponsored Posts
    • Advertise
    • Privacy Policy
    • Endpoints Merch
    • About Us
    • Help
  • SIGN UP

Bruised by a pun­ish­ing Op­di­vo fail­ure, Bris­tol-My­ers looks to shake up the busi­ness, ac­cel­er­ate R&D

9 years ago
R&D

Al­ler­gan’s ex­ec­u­tive team or­ches­trates a $200M buy­out to beef up gas­troen­terol­o­gy pipeline

9 years ago
Deals

Turn­ing phar­ma castoffs in­to an in­stant for­tune, Vivek Ra­maswamy’s My­ovant bags a $218M IPO

9 years ago
Financing

Hu­mana spells out its con­di­tion­al Ex­ondys 51 cov­er­age pol­i­cy — strings at­tached

9 years ago
Pharma

Au­ven Ther­a­peu­tics sells PhI­II dry eye dis­ease drug to Sun for $40M-plus

9 years ago
Pharma

GV backs new ge­nomics R&D up­start; Ver­tex ad­vances plans for next-gen CF drugs

9 years ago
News Briefing

Glax­o­SmithK­line sounds taps for a once-mighty R&D pro­gram

9 years ago
R&D

Boehringer flags PhI­II suc­cess for an­oth­er Hu­mi­ra knock­off, set­ting up a crowd­ed field of cheap­er ri­vals — ...

9 years ago
R&D

Bio­gen qui­et­ly whisks away its $544M au­toim­mune ri­val to Cel­gene

9 years ago
R&D

Mer­ck and No­var­tis chiefs out­line what's on the M&A menu in 2017

9 years ago
R&D

As­traZeneca cel­e­brates a PhI­II PARP suc­cess for Lyn­parza, putting pres­sure on Tesaro ri­val

9 years ago
R&D

The clock is tick­ing on Eli Lil­ly’s big Alzheimer’s gam­ble; Pluris­tem reach­es terms on $30M in­vest­ment from Chi­na ...

9 years ago
News Briefing

Por­to­la caps a prob­lem-plagued year with an ap­pli­ca­tion for an­ti­co­ag­u­lant be­trix­a­ban

9 years ago
R&D

Dipex­i­um shares evis­cer­at­ed af­ter lead an­tibi­ot­ic flops on a full slate of PhI­II end­points

9 years ago
R&D

No­var­tis promis­es a speedy CAR-T pitch, boasts about its slate of block­busters-to-be

9 years ago
R&D
Pharma

Why wait? FDA gives ear­ly OK to Mer­ck’s Keytru­da for front­line lung can­cer

9 years ago
Pharma

FDA clears Glob­al Blood Ther­a­peu­tics to fo­cus on key bio­mark­er in piv­otal sick­le cell tri­al

9 years ago
Pharma

Back­lash: Har­vard ex­perts fret over the fall­out from FDA’s OK for Sarep­ta’s con­tro­ver­sial Duchenne drug

9 years ago
R&D

Chi­na: Fraud not the on­ly rea­son 1,193 drug ap­pli­ca­tions were with­drawn; Ad­vax­is shares drop

9 years ago
News Briefing

In­ovio shares slide af­ter FDA hits it with a hold on lead PhI­II HPV pro­gram

9 years ago
R&D

New Lis­te­ria fears spot­light­ed as Aduro’s CRS-207 is slapped with par­tial hold

9 years ago
R&D

Shire bids CTI and its trou­bled myelofi­bro­sis drug adieu, buy­ing its way out of a deal

9 years ago
R&D

Ze­ro­ing in on Mer­ck ri­val, GSK steps up to the FDA with its top new vac­cine prospect

9 years ago
R&D

Mer­ck com­pletes a clin­i­cal tri­al Odyssey, fi­nal­ly bag­ging an FDA OK for C diff an­ti­body

9 years ago
R&D
First page Previous page 1149115011511152115311541155 Next page Last page
Endpoints News

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas

Latest

  • All News
  • Special
  • In Focus

Channels

  • AI
  • Bioregnum
  • Biotech Voices
  • Cell/Gene Tx
  • China
  • Coronavirus
  • Deals
  • Diagnostics
  • Discovery
  • FDA+
  • Financing
  • Health Tech
  • Law
  • Letters to the Editor
  • Manufacturing
  • Marketing
  • Nikkei Biotechnology
  • Opinion
  • Outsourcing
  • Peer Review
  • People
  • Pharma
  • R&D
  • Startups
  • Weekly

More

  • Work at Endpoints
  • Letter to Editors
  • Editorial Standards
  • IPO Tracker
  • Events
  • Webinars
  • Sponsored Posts
  • Advertise
  • Endpoints Merch
  • About Us
  • Help

Work in biotech

  • Endpoints Careers

© Endpoints News 2025

  • Help
  • Advertise
  • Privacy Policy
  • Business Model
FT Specialist Logo
A service from the Financial Times
Endpoints News

Log in to your account

email

password

Endpoints News

request login link

Enter the email associated to with your Endpoints account, and we'll send you a one-time login link (no password needed). The link expires after 24 hours.

email

Endpoints News

reset password

Enter the email associated to with your Endpoints account, and we'll send you a link to reset your password. The link expires after 24 hours and can only be used once.

email

Endpoints News

Sign up for free to read a limited number of articles each month.

About You

Newsletter Interests

Pick what newsletters get delivered to your inbox each week.

Biopharma

ENDPOINTS NEWS Daily at 11:30 AM ET

EARLY EDITION Daily at 7:15 AM ET

ENDPOINTS PHARMA Daily at 3:30 PM ET

BREAKING NEWS ALERTS 2-3 times a week

ENDPOINTS FDA+ Wed at 2 PM ET

ENDPOINTS MANUFACTURING Thu at 2 PM ET

ENDPOINTS WEEKLY Sat at 6 AM ET

POST-HOC 1-2 times a week

Healthcare

ENDPOINTS HEALTH TECH Tuesday, Thursday at 10 AM ET

BREAKING NEWS ALERTS 2-3 times a week

Want unlimited access? Sign up for a premium subscription plan.